administer Subtitle B, “Incentives for the Use of Health Information Technology,” sections 3011 through 3017, with the exception of 3012(c)(5), the Financial Support subsection.

These authorities may be redelegated. The delegations authorize the National Coordinator to administer the Incentives for the Use of Health Information Technology as provided in Subtitle B.

I hereby affirm and ratify any actions taken by the National Coordinator or by any other officials of the Office of the National Coordinator for Health Information Technology, which, in effect, involved the exercise of this authority prior to the effective date of this delegation.

This delegation is effective upon date of signature.

Kathleen Sebelius,
Secretary.
[FR Doc. E9–19709 Filed 8–17–09; 8:45 am]
BILLING CODE 4150–24–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

Ryan M. Wolfort, M.D., Ph.D., Louisiana State University Health Sciences Center—Shreveport: Based on the report of an investigation conducted by Louisiana State University Health Sciences Center—Shreveport (LSUHSC–S) and additional analysis conducted by ORI in its oversight review, the U.S. Public Health Service (PHS) found that Dr. Ryan M. Wolfort, who was a House Officer in the Department of Surgery, and a former graduate student, Department of Molecular and Cellular Physiology, LSUHSC–S, engaged in research misconduct in the reporting of research supported by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL24441 and P01 HL55552. Respondent’s research misconduct related to his dissertation research as a graduate student, which he undertook at the same time that he also was serving as a House Officer at LSUHSC–S. ORI acknowledges Dr. Wolfort’s cooperation with the LSUHSC–S misconduct proceedings.

PHS found that Dr. Wolfort engaged in research misconduct by falsifying and fabricating data reported in three publications and one manuscript that had been submitted for publication, reviewed, and returned for revision. Specifically, Dr. Wolfort falsified and fabricated data reported in research examining the contribution of immune mechanisms to early oxidative stress and endothelial dysfunction in mice with induced dietary hypercholesterolemia by:

1. Admittedly fabricating tabulations and the associated statistical analyses of RT–PCR data on Nox-2 mRNA expression in the three publications and the manuscript;

2. Falsifying data and the associated statistical claims, specifically by (a) Admittedly falsifying the measurements of endothelial function by myographic recordings of aortic ring dilation in reaction to vasoactive substances in the three papers and manuscript, (b) admitting falsifying the measurement of cytokine by cytometric bead assay in paper 3, and (c) falsifying the measurement of superoxide production by cytochrome c reduction in papers 1 and 2, for which the underlying spreadsheet data the Respondent claims were unintentionally misrepresented, massaged, and improperly collated, but for which Respondent acknowledges that the raw data were missing for all three papers, admittedly because he intentionally erased files and discarded notebooks.

Dr. Wolfort has entered into a Voluntary Exclusion Agreement in which he has voluntarily agreed, for a period of two (2) years, beginning on July 13, 2009:

1. Admittedly fabricating tabulations and the associated statistical analyses of RT–PCR data on Nox-2 mRNA expression in the three publications and the manuscript;

2. Falsifying data and the associated statistical claims, specifically by (a) Admittedly falsifying the measurements of endothelial function by myographic recordings of aortic ring dilation in reaction to vasoactive substances in the three papers and manuscript, (b) admitting falsifying the measurement of cytokine by cytometric bead assay in paper 3, and (c) falsifying the measurement of superoxide production by cytochrome c reduction in papers 1 and 2, for which the underlying spreadsheet data the Respondent claims were unintentionally misrepresented, massaged, and improperly collated, but for which Respondent acknowledges that the raw data were missing for all three papers, admittedly because he intentionally erased files and discarded notebooks.

3. Falsifying the measurement of superoxide production by cytochrome c reduction in paper 2.

4. Falsifying the measurements of endothelial function by myographic recordings of aortic ring dilation in reaction to vasoactive substances in paper 2.

5. Falsifying the measurement of superoxide production by cytochrome c reduction in paper 1.

6. Falsifying the measurements of endothelial function by myographic recordings of aortic ring dilation in reaction to vasoactive substances in paper 1.

7. Falsifying and fabricating data reported in research examining the contribution of immune mechanisms to early oxidative stress and endothelial dysfunction in mice with induced dietary hypercholesterolemia by:

1. Admittedly fabricating tabulations and the associated statistical analyses of RT–PCR data on Nox-2 mRNA expression in the three publications and the manuscript;

2. Admittedly falsifying the measurement of cytokine by cytometric bead assay in paper 3;

3. Falsifying the measurement of superoxide production by cytochrome c reduction in papers 1 and 2.

4. Falsifying the measurement of superoxide production by cytochrome c reduction in paper 3.

5. Falsifying the measurements of endothelial function by myographic recordings of aortic ring dilation in reaction to vasoactive substances in paper 3.

6. Falsifying the measurement of superoxide production by cytochrome c reduction in paper 2.

7. Falsifying the measurements of endothelial function by myographic recordings of aortic ring dilation in reaction to vasoactive substances in paper 2.

8. Falsifying and fabricating data reported in research examining the contribution of immune mechanisms to early oxidative stress and endothelial dysfunction in mice with induced dietary hypercholesterolemia by:

1. Admittedly fabricating tabulations and the associated statistical analyses of RT–PCR data on Nox-2 mRNA expression in the three publications and the manuscript;

2. Falsifying data and the associated statistical claims, specifically by (a) Admittedly falsifying the measurements of endothelial function by myographic recordings of aortic ring dilation in reaction to vasoactive substances in the three papers and manuscript, (b) admitting falsifying the measurement of cytokine by cytometric bead assay in paper 3, and (c) falsifying the measurement of superoxide production by cytochrome c reduction in papers 1 and 2, for which the underlying spreadsheet data the Respondent claims were unintentionally misrepresented, massaged, and improperly collated, but for which Respondent acknowledges that the raw data were missing for all three papers, admittedly because he intentionally erased files and discarded notebooks.

Dr. Wolfort has agreed to the following:

1. To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States pursuant to HHS’ Implementation (2 CFR part 276 et seq.) of OMB Guidelines to Agencies on Government wide Debarment and Suspension (2 CFR, part 180); and

2. To exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852. [240] 453–8800.

John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. E9–19795 Filed 8–17–09; 8:45 am]
BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Notice of Interest Rate on Overdue Debts

Section 30.18 of the Department of Health and Human Services’ claims collection regulations (45 CFR Part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS becomes entitled to recovery. The rate generally cannot be lower than the Department of Treasury’s current value of funds rate or the applicable rate determined from the “Schedule of Certified Interest Rates with Range of Maturities.” This rate may be revised quarterly by the Secretary of the Treasury and shall be published quarterly by the Department of Health and Human Services in the Federal Register.

The Secretary of the Treasury has certified a rate of 11¼% for the quarter ended June 30, 2009. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: August 6, 2009.
Molly P. Dawson,
Director, Office of Financial Policy and Reporting.